Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

International Journal of Neuropsychopharmacology

Volumn 6, Issue 4, 2003, Pages 325-337

  Kasper, Siegfried ^a   Lerman, Mark N ^b   McQuade, Robert D ^c   Saha, Anutosh ^d   Carson, William H ^d   Ali, Mirza ^d   Archibald, Donald ^c   Ingenito, Gary ^d   Marcus, Ronald ^c   Pigott, Teresa ^e  

^a UNIVERSITY OF VIENNA   (Austria)

^b Alexian Brothers Behavioral Health Hospital   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Dopamine partial agonist; Long term treatment; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PROLACTIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ADULT; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; CHRONIC DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HEART ARREST; HUMAN; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PANSS NEGATIVE SUBSCALE SCORE; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SUICIDE; TREMOR; WEIGHT GAIN;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; LONG-TERM CARE; MALE; NEUROLOGIC EXAMINATION; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 9144237416     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003651     Document Type: Article

References (36)

1. Allison DB, Casey DE (2001). Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62, 22-31.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
3. Buchanan RW, Brandes M, Breier A (1996). In: Breier A (Ed.), The New Pharmacotherapy of Schizophrenia (pp. 179-197). Washington, DC: American Psychiatric Press, Inc.
4. 2 dopamine receptors. Journal of Pharmacology and Experimental Therapeutics 302, 381-389.
5. Carlsson A, Waters N, Waters S, Carlsson ML (2000). Network interactions in schizophrenia - therapeutic implications. Brain Research Reviews 31, 342-349.
6. Carson WH, Stock E, Saha AR, Ali M, McQuade RD, Kujawa MJ, Ingenito G (2002). Meta-analysis of efficacy with aripiprazole [Abstract]. Schizophrenia Research 53 (Suppl. 3), 1-274, Abstract B96.
7. Casey DE (2001). Barriers to progress - the impact of tolerability problems. International Clinical Pyschopharmacology 16 (Suppl. 1), S15-S19.
8. Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986). The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 148, 120-127.
9. Csernansky JG, Mahmoud R, Brenner R, for the Risperidone USA 79 Study Group (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 346, 16-22.
10. Fleischhacker WW, Meise U, Gunther V, Kurz M (1994). Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scandinavica 382 (Suppl.), 11-15.
11. Glennon RA, Dukat M (1995). Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology: The Fourth Generation of Progress (p. 419). New York: Raven Press.
12. Glick ID, Berg PH (2002). Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. International Clinical Pyschopharmacology 17, 65-68.
13. Gury C, Canceil O, Iaria P (2000). Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 26, 62-72.
14. Iyer RN, Davis MD, Juneau PL, Giordani AB (1998). Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat. Journal of Pharmacy and Pharmacology 50, 1147-1153.
15. 1A receptor. European Journal of Pharmacology 441, 137-140.
16. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GC, Zimbroff DL, Ali MW (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 63, 763-771.
17. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J (1982). Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry 39, 70-73.
18. Kasper S (1998). Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. International Clinical Psychopharmacology 13, 253-262.
19. Kasper S (1999). First-episode schizophrenia - the importance of early intervention and subjective tolerability. Journal of Clinical Psychiatry 60 (Suppl. 23), 5-9.
20. Kasper S (2000). Clinical decisions (algorithms) in the pharmacotherapy of schizophrenia. Japanese Journal of Neurospychopharmacology 20, 273.
21. Kasper S, Hale AS, Azorin JM, Möller HJ (1999a). Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 249 (Suppl. 2), 2-14.
22. Kasper S, Tauscher J, Küfferle B, Barnas C, Pezawas L, Quiner S (1999b). Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 249 (Suppl. 4), 83-89.
23. Keck Jr. PE, Strakowski SM, McElroy SL (2000). The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia. Journal of Clinical Psychiatry 61 (Suppl. 3), 4-9.
24. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998). Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in schizophrenia. Biological Psychiatry 43, 2-11.
25. Launois R, Schulenberg M, Knapp M, Mondher T (1998). Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model. International Journal of Psychiatry and Clinical Practice 2 (Suppl. 2), S79-S86.
26. 2 receptors. Psychopharmacology 112, S4.
27. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha AR, Ali MW, Iwamoto T (2003). Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophrenia Research 61, 123-136.
28. McQuade R, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T (2002). Aripiprazole: a dopamine-serotonin system stabilizer. International Journal of Neuropsychopharmacology 5 (Suppl. 1), S176.
29. 1A receptors. Journal of Pharmacology and Experimental Therapeutics 295, 853-861.
30. National Heart, Lung, and Blood Institute, in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases (1998). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Institutes of Health.
31. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali MW, Stock E, Stringfellow J, Ingenito GG, Marder SR (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 60, 681-690.
32. Rao ML, Möller HJ (1994). Biochemical findings of negative symptoms in schizophrenia and their positive relevance to pharmacologic treatment. Neuropsychobiology 30, 160-164.
33. Sramek JJ, Eldon MA, Posvar EL, Feng MR, Jhee SS, Hourani J, Sedman AJ, Cutler NR (1998). Initial safety, tolerability, pharmacodynamics and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharmacology Bulletin 34, 93-99.
34. Sussman N (2001). Review of atypical antipsychotics and weight gain. Journal of Clinical Psychiatry 62 (Suppl. 23), 5-12.
35. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefon GD (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 17, 407-418.
36. Weiden P, Glazer W (1997). Assessment and treatment selection for 'revolving door' inpatients with schizophrenia. Psychiatry Quarterly 68, 377-392.